Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy.

about

Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy.

Item

http://www.wikidata.org/entity/Q36540329

description

2016 nî lūn-bûn

@nan

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

name

Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy.

@ast

Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy.

@en

type

Item

label

Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy.

@ast

Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy.

@en

prefLabel

Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy.

@ast

Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy.

@en

P1476

Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy.

@en

P2093

Ayako Tanaka

http://www.w3.org/2001/XMLSchema#string

Hidekazu Suzuki

http://www.w3.org/2001/XMLSchema#string

Manabu Hayama

http://www.w3.org/2001/XMLSchema#string

Motohiro Tamiya

http://www.w3.org/2001/XMLSchema#string

Naoko Morishita

http://www.w3.org/2001/XMLSchema#string

Norio Okamoto

http://www.w3.org/2001/XMLSchema#string

Takashi Nishihara

http://www.w3.org/2001/XMLSchema#string

Takayuki Shiroyama

http://www.w3.org/2001/XMLSchema#string

Takuji Nishida

http://www.w3.org/2001/XMLSchema#string

Tomonori Hirashima

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Cancer statistics, 2015

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis

Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.

Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group.

Use of chemotherapy at the end of life in Turkey.

P304

116-123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2072-1439.2016.01.42

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26904219

http://www.w3.org/2001/XMLSchema#string

P932

4740147

http://www.w3.org/2001/XMLSchema#string